Mortality: a neglected outcome in OCS-treated severe asthma

Severe asthma, especially if associated with a T2 phenotype, often responds well to new emerging therapies, which have led to a reduction in the use of systemic oral corticosteroids (OCS) [1]. However, OCS-dependent patients still exist and are affected by the well-known (and potentially severe) side effects of such dependency. Longitudinal data that document the outcomes, including death, for these patients are lacking [2]. Here, we present our findings from a long-term severe asthma cohort, which indicate that mortality is a critical issue for these patients. Findings from a long-term severe asthma cohort indicate mortality is a critical issue for OCS-dependent patients <http://ow.ly/rO8e30fZrPo>